Key Updates
Berkshire Hathaway shares rebounded 2.04% to $722,500 since the January 28 report, partially recovering from the recent decline but remaining down 4.28% YTD. The single news event during this period—completion of the $9.7 billion OxyChem acquisition—represents a significant capital deployment milestone that addresses ongoing concerns about the company's record cash position. This marks Berkshire's largest acquisition since the $11.6 billion Alleghany purchase in 2022 and demonstrates new CEO Greg Abel's ability to execute meaningful transactions. The rebound suggests the market views this strategic deployment positively, though broader concerns about the Kraft Heinz stake and post-Buffett transition remain in focus.
Current Trend
BRK-A trades at $722,500, down 4.28% YTD despite the recent 2.04% recovery. Short-term momentum shows improvement with a 1.19% daily gain and 0.22% weekly advance, though the monthly performance remains negative at -4.28%. The 6-month performance of 1.17% indicates consolidation within a broader range. The stock continues to trade below levels seen at year-end 2025, reflecting ongoing market adjustment to the CEO transition and portfolio management decisions. Recent price action suggests stabilization around current levels following the sharp declines in mid-January tied to the Kraft Heinz divestiture announcement. The 2.04% gain since the last report marks the first meaningful recovery after three consecutive negative reporting periods.
Investment Thesis
The investment thesis centers on Berkshire's evolution under new leadership, balancing a $381.6 billion cash position with strategic capital deployment opportunities. The OxyChem acquisition validates Abel's capacity to execute large-scale transactions while expanding Berkshire's industrial footprint into essential chemical manufacturing. The thesis depends on three pillars: effective deployment of record cash reserves into accretive acquisitions, portfolio optimization through divestiture of underperforming holdings like Kraft Heinz, and operational excellence across diversified business segments including insurance, rail, utilities, and manufacturing. The company's trillion-dollar market capitalization and diversified revenue streams provide resilience, though the transition from Buffett's six-decade leadership introduces execution risk. Long-term value creation hinges on Abel's ability to maintain Berkshire's disciplined capital allocation culture while adapting to contemporary market conditions.
Thesis Status
The thesis shows early validation with mixed execution. The OxyChem acquisition completion directly addresses the primary concern about capital deployment, representing meaningful progress in reducing the cash stockpile while acquiring a top-three U.S. producer across multiple chemical categories. This strategic addition to Berkshire's manufacturing segment demonstrates Abel's willingness to pursue substantial transactions. However, the ongoing Kraft Heinz situation—with potential divestiture of the entire 28% stake following a 70% decline since the 2015 merger—highlights portfolio challenges inherited from the Buffett era. The YTD underperformance of -4.28% versus broader market strength suggests investor caution about the transition, though recent stabilization indicates the market is beginning to assess Abel's tenure on its own merits rather than purely through the lens of Buffett's departure.
Key Drivers
The completed $9.7 billion OxyChem acquisition represents the primary near-term catalyst, adding a leading chemical manufacturer with operations across the U.S., Canada, and Latin America. OxyChem ranks among the top three U.S. producers of polyvinyl chloride, chlor-alkali, chlorinated organic chemicals, and calcium chloride, supplying essential materials for water treatment, pharmaceuticals, healthcare, manufacturing, and construction. The business will maintain its current leadership under president and CEO Wade Alleman, consistent with Berkshire's decentralized operating model. This acquisition reduces the cash position by approximately 2.5% while adding diversified industrial exposure. The Kraft Heinz portfolio resolution remains a secondary driver, with the registration statement providing flexibility to exit the 28% stake, though no immediate sale is signaled. The broader context includes pressure on Abel to deploy capital effectively as the company holds record liquidity.
Technical Analysis
BRK-A recovered 2.04% to $722,500, establishing a near-term support level after the decline to $708,085 in the previous period. The stock trades approximately 4.28% below year-end 2025 levels, with recent price action suggesting consolidation in the $700,000-$740,000 range. The 1.19% daily gain and 0.22% weekly advance indicate short-term momentum stabilization, though the negative monthly (-4.28%) and YTD (-4.28%) performance reflects continued pressure. The 6-month gain of 1.17% demonstrates longer-term range-bound behavior. Previous analysis noted a bullish "golden cross" pattern formed in early 2026, with the 50-day moving average crossing above the 200-day average, historically associated with approximately 30% average gains in subsequent periods. Current price action suggests the stock is building a base following the January selloff related to the Kraft Heinz news, with the OxyChem acquisition providing fundamental support for potential upside continuation.
Bull Case
- OxyChem acquisition demonstrates capital deployment capability: The $9.7 billion transaction adds a top-three U.S. chemical producer with diversified operations across essential industrial applications, validating new CEO Greg Abel's ability to execute meaningful acquisitions and begin reducing the record $381.6 billion cash position.
- Buffett endorsement provides credibility to Abel's leadership: Warren Buffett stated in his final CEO interview that Berkshire has the best odds of any company to last a century and gave strong endorsement to successor Greg Abel, providing confidence in the leadership transition for the trillion-dollar conglomerate.
- Technical golden cross pattern signals upside potential: The bullish "golden cross" chart pattern formed in early 2026, with historical data showing Berkshire shares have averaged approximately 30% gains following the 14 previous golden crosses over the past 25 years.
- Portfolio optimization through Kraft Heinz exit removes drag: The potential divestiture of the underperforming Kraft Heinz stake (down 70% since 2015 merger) allows Abel to move past a rare investment misstep and redeploy capital into higher-return opportunities, with proceeds potentially funding additional acquisitions.
- Record cash position provides acquisition firepower: Berkshire's $381.7 billion in cash and equivalents as of September 30 provides substantial capacity for large-scale acquisitions, with the OxyChem deal representing only 2.5% of available liquidity and demonstrating willingness to deploy capital at scale.
Bear Case
- Kraft Heinz represents worst-performing holding with $3.8 billion writedown: The food company has been Berkshire's worst performer over five years, plunging approximately 70% since the 2015 merger, with Berkshire taking a $3.8 billion writedown last year, highlighting portfolio management challenges and potential for additional legacy position issues.
- Limited acquisition opportunities at reasonable valuations constrain growth: Despite expressing willingness to deploy up to $100 billion on acquisitions, Buffett found no suitable large-scale opportunities at reasonable valuations throughout 2025, with the OxyChem deal at $9.7 billion representing the only major transaction since the $11.6 billion Alleghany acquisition in 2022.
- Buffett's wealth distribution plan may expose company to shareholder activism: Warren Buffett's plan to donate 99% of his $148 billion Berkshire wealth within 10 years of estate settlement could dilute voting control and expose the conglomerate to shareholder activism for the first time in six decades, potentially pressuring management for clearer capital allocation strategies.
- Recent underperformance versus S&P 500 raises valuation concerns: Berkshire shares gained 10.9% in 2025, underperforming the S&P 500's 16.4% rise, while shares declined 7.6% since Buffett's retirement announcement in May, reflecting investor concerns about whether Abel can maintain the premium valuation commanded under Buffett's leadership.
- Major portfolio reductions signal limited conviction in core holdings: Berkshire significantly reduced positions in Apple and Bank of America during 2025, contributing to the cash buildup, with the equity portfolio totaling $283.2 billion at end of September, suggesting limited opportunities for deployment and potential concerns about current market valuations.